What You Should Know About the Recent Xanax Recall

If you have a prescription for the anti-anxiety medication Xanax (alprazolam), check your bottle.

On March 17, the Food and Drug Administration (FDA) listed a voluntary recall of one lot of the drug that failed a quality check. The recall was initiated by Viatris, the pharmaceutical company that makes brand-name Xanax.

The recalled medication includes 3-milligram pills of brand-name Xanax XR in bottles of 60 tablets. These are the “extended release” version of the drug. If you take generic alprazolam, this recall doesn’t affect you.

According to the enforcement report, the recall is classified as Class II, which means that if you use the recalled medication, you may experience “temporary or medically reversible adverse health consequences,” and the “probability of serious adverse health consequences is remote.”

This is not the most severe level of recall, but the batch of pills that failed quality tests may not dissolve the way they’re supposed to, potentially affecting how the active ingredients are released in the body. If a medication doesn’t dissolve properly, it might affect how much of the active ingredient actually gets into your bloodstream.

Pills with the lot number 8177156 and an expiration date of 02/28/2027 are being recalled. They were distributed to patients between 08/27/2024 and 05/29/2025, per a notice issued by the California State Board of Pharmacy. This is a voluntary recall at the retailer level, which means patients don’t need to take any action. Viatris said retailers such as pharmacies have been provided with instructions on how to return the pills.

If you’re worried about whether your Xanax is in the recall, talk to your doctor or pharmacist. You should never stop taking a medication like Xanax suddenly. Benzodiazepines can cause serious withdrawal.

9 Sources

Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Food and Drug Administration (FDA). Enforcement report. 

  2. FDA. Recalls and background definitions. 

  3. Food and Drug Administration (FDA). Dissolution testing and acceptance criteria for immediate-release SOLID oral dosage form drug products containing high solubility drug substances guidance for industry.

  4. Food and Drug Administration (FDA). Guidance for industry dissolution testing of immediate release solid oral dosage forms.

  5. Food and Drug Administration(FDA). Extended release oral dosage forms: development, evaluation, and application of in vitro/in Vivo correlations.

  6. Food and Drug Administration (FDA). Draft guidance on alprazolam.

  7. California State Board of Pharmacy. Notice.

  8. Thornton SL, Whitacre J, Pallo N, Roberts N, Oller L. Retrospective review of morbidity and mortality associated with acute benzodiazepine withdrawal at a Midwestern academic medical center. Kans J Med. 2021;14:77-79. doi:10.17161/kjm.vol1414653

  9. Maust DT, Petzold K, Strominger J, Kim HM, Bohnert ASB. Benzodiazepine discontinuation and mortality among patients receiving long-term benzodiazepine therapy. JAMA Netw Open. 2023;6(12):e2348557. doi:10.1001/jamanetworkopen.2023.48557

Healthcare writer and editor

By Abby Norman

Abby Norman is a writer and editor with more than a decade of experience in the healthcare industry.

Related Posts

Leave a Reply

Your email address will not be published. Required fields are marked *

© 2026 - WordPress Theme by WPEnjoy